The herpesvirus accessory protein γ134.5 facilitates viral replication by disabling mitochondrial translocation of RIG-I

Xing Liu1, Yijie Ma1, Kathleen Voss2, Michiel van Gent3,4, Ying Kai Chan5,6, Michaela U. Gack3,4, Michael Gale, Jr2, Bin He1*

1 Department of Microbiology and Immunology University of Illinois College of Medicine, Chicago, Illinois, United States of America, 2 Center for Innate Immunity and Immune Disease, Department Immunology, University of Washington, Seattle, Washington, United States of America, 3 Florida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, Florida, United States of America, 4 Department of Microbiology, The University of Chicago, Illinois, United States of America, 5 Department of Genetics, Harvard Medical School, Boston, Massachusetts, United States of America, 6 Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts, United States of America

* tshuo@uic.edu

Abstract

RIG-I and MDA5 are cytoplasmic RNA sensors that mediate cell intrinsic immunity against viral pathogens. While it has been well-established that RIG-I and MDA5 recognize RNA viruses, their interactive network with DNA viruses, including herpes simplex virus 1 (HSV-1), remains less clear. Using a combination of RNA-deep sequencing and genetic studies, we show that the γ134.5 gene product, a virus-encoded virulence factor, enables HSV growth by neutralization of RIG-I dependent restriction. When expressed in mammalian cells, HSV-1 γ134.5 targets RIG-I, which cripples cytosolic RNA sensing and subsequently suppresses antiviral gene expression. Rather than inhibition of RIG-I K63-linked ubiquitination, the γ134.5 protein precludes the assembly of RIG-I and cellular chaperone 14-3-3ε into an active complex for mitochondrial translocation. The γ134.5-mediated inhibition of RIG-I-14-3-3ε binding abrogates the access of RIG-I to mitochondrial antiviral-signaling protein (MAVS) and activation of interferon regulatory factor 3. As such, unlike wild type virus HSV-1, a recombinant HSV-1 in which γ134.5 is deleted elicits efficient cytokine induction and replicates poorly, while genetic ablation of RIG-I expression, but not of MDA5 expression, rescues viral growth. Collectively, these findings suggest that viral suppression of cytosolic RNA sensing is a key determinant in the evolutionary arms race of a large DNA virus and its host.

Author summary

Host cytosolic RNA sensing has been implicated in the recognition of herpesvirus infection. As such, herpesviruses likely have evolved strategies to escape this host surveillance mechanism; however, molecular insight into antagonism of RNA sensors by herpesviruses remains largely elusive. We show that the γ134.5 protein encoded by herpes simplex virus
I inactivates the helicase RIG-I that serves as an RNA receptor. Viral γ134.5 hijacks RIG-I and selectively inhibits its engagement with the chaperone protein 14-3-3ε in the cytoplasm of infected cells. Targeting of RIG-I by γ134.5 blocks the cytosol-to-mitochondrial translocation of RIG-I, which ultimately dampens antiviral innate immunity. Finally, depletion of RIG-I enhances the growth of a recombinant HSV-1 in which γ134.5 was deleted. Our work provides insights into viral modulation of intracellular RNA recognition in herpesvirus infection, which in turn may guide the rational development of therapeutic agents.

Introduction

The RIG-I-like receptors (RLR), which include RIG-I (retinoic acid-inducible gene-I), MDA5 (melanoma differentiation-associated gene 5), and LGP2 (laboratory of genetics and physiology 2), are best known to recognize RNA viruses [1,2]. Once bound to double-stranded RNA ligands, RLRs recruit mitochondrial antiviral-signaling protein (MAVS) to activate nuclear factor κB (NF-κB) and interferon (IFN)-regulatory factor 3 (IRF3). Whereas LGP2 regulates innate immune signaling, RIG-I and MDA5 mediate the production of IFN-α/β, other cytokines and IFN-stimulated genes (ISGs).

The RIG-I protein consists of two caspase activation and recruitment domains at its N terminus, a helicase domain and a C-terminal domain [3]. Whereas RIG-I is in a closed, inactive conformation in uninfected cells, it adopts conformational changes upon activation by RNA viruses; this, then triggers RIG-I dephosphorylation, its K63-linked ubiquitination and mitochondrial translocation [2,4]. In this process, protein phosphatase 1, the ubiquitin ligases TRIM25 and Riplet, and the chaperone protein 14-3-3ε cooperatively allow RIG-I to activate downstream targets, resulting in an antiviral state [5–8]. Emerging evidence also pinpoints to a role of RIG-I in the detection of DNA viruses [2,9]. RIG-I recognizes multiple RNAs of Kaposi’s sarcoma-associated herpesvirus (KSHV) and host-derived 5’-ppp-vRNA, which triggers IFN production and limits KSHV reactivation from latency [10–12]. In latently infected B cells, RIG-I binds to small noncoding RNA encoded by Epstein-Barr virus (EBV) to drive IL-10 production [13,14]. Remarkably, herpes simplex virus 1 (HSV-1) triggers RIG-I activation via RNA polymerase III that generates 5’-ppp RNA species, including host 5S ribosomal pseudogene transcripts due to virus-mediated depletion of specific RNA-binding proteins [15,16].

HSV-1 is an alphaherpesvirus associated with recurrent orofacial infection and remains the most common cause of viral encephalitis [17]. Upon infection, over 90 viral proteins are synthesized sequentially to facilitate viral persistence. Among them is the accessory protein γ134.5 that is conserved between HSV-1 and HSV-2 [18–20]. The γ134.5 protein critically mediates viral replication and penetration of the nervous system [18–20]. Accordingly, deletion of the γ134.5 gene renders the virus avirulent, which is recently exploited for oncolytic HSV immunotherapy in humans [21–23]. How HSV-host interactions influence oncolytic HSV immunotherapy is largely unknown [24].

It has long been known that HSV-1 prevents translation arrest by double-stranded RNA-dependent protein kinase (PKR) through γ134.5 [19,25,26]. Paradoxically, PKR inhibition per se does not restore viral virulence [27,28]. Previous work suggested that γ134.5 is involved in HSV glycoprotein processing as well as nuclear egress [29–31]. Although the γ134.5 protein suppresses autophagy [32], it appears dispensable for virus replication in non-neuronal cells where autophagy plays an important role in virus restriction [33]. HSV-1 γ134.5 also inactivates the stimulator of interferon gene (STING), which only partially rescues viral growth [34].
To unravel key mechanisms of viral replication, we performed global gene expression and genetic analyses. We show that HSV-1 subverts RIG-I-mediated cytosolic RNA sensing via the γ134.5 protein. Mechanistically, γ134.5 targets RIG-I, which precludes the assembly of RIG-I and the chaperone 14-3-3ε into a translocon complex necessary for RIG-I translocation from the cytosol to mitochondria. As such, HSV-1 γ134.5 inactivates RIG-I, which promotes effective viral replication.

**Results**

**HSV-1 regulates host genes linked to cytosolic RNA recognition**

To gain insight into HSV replication, we examined global gene expression in response to virus infection by RNA deep sequencing. Among diverse host genes, we observed a range of...
differentially up or downregulated ones by wild type HSV-1 and the γ134.5 null mutant (Fig 1A). Several innate immune factors were also upregulated. Built on this initial assessment, we sought to define the functional pathways upregulated by the γ134.5 null mutant relative to wild type virus. Gene Set Enrichment Analysis (GSEA) identified distinct pathways enriched (FDR q value < 0.25), which included the IFN-α/γ response, protein secretion, xenobiotic metabolism, bile acid metabolism, and epithelial mesenchymal transition (Fig 1B) [35].

Given the normalized enhancement scores closely coupled with the IFN pathways (Figs 1B and S1), we surveyed innate immune genes. This revealed unique patterns of RNA transcripts that were differentially accumulated (Fig 1C). We found that both viruses upregulated many IFN-related genes relative to the mock control, which reflects the cellular antiviral response. A more detailed comparative analysis of the genes upregulated by wild type vs mutant HSV-1 revealed several distinct features. The γ134.5 null mutant, compared to wild type virus, highly stimulated a spectrum of IFN effector molecules, including Ifit1 (Isg56), Isg15, Sp100, Gbp5, Oasl2, Mx1, and Ifgga3. Moreover, As compared to the wild type virus, the γ134.5 null mutant strongly increased transcript abundance of several DNA sensors (e.g. Ifi203, Ifi204, and Ifi205) that mediate antiviral gene induction in response to DNA ligands [36–38]. This data is in line with the fact that HSV-1 inactivates STING, a critical adaptor downstream of many DNA sensors, via the γ134.5 gene product [34]. Importantly, the γ134.5 null mutant exhibited propensity to induce more transcripts of Ddx60, Ddx58 (RIG-I), Dhx58 (LGP2), Ifih1 (MDA5) and Zbp1, which are prominent components of cytosolic RNA sensing pathways that regulate cytokine induction and necroptosis [1,39]. We also noted that wild type virus and the γ134.5 null mutant comparably induced a subset of IFN-stimulated genes such as Mx2, Oas3 and Oasl1. These heterogeneous responses are likely attributable to a complex regulation of individual IFN-stimulated genes. We validated the RNAseq results by performing qPCR analysis of representative genes, which confirmed increased antiviral gene expression in the absence of γ134.5 (Fig 1D). These results raised the possibility that besides intracellular DNA recognition, γ134.5 might modulate cytosolic RNA sensing.

The RIG-I-γ134.5 axis influences the innate immune response

Several lines of evidence show that HSV-1 triggers RIG-I to initiate antiviral signaling [2,9,15]. As wild type virus, unlike Δγ134.5, favorably attenuated the IFN response, we reasoned that γ134.5 might modulate innate immunity mediated by RIG-I. To probe this, we examined the induction of cytokines and ISGs by wild type HSV-1 and the γ134.5 null virus in the presence or absence of RIG-I. In Rig-I+/+ mouse embryonic fibroblast (MEF) cells, wild type virus modestly induced the expression of IFN-β, Ifit1, Ifit2 (Isg54) and Ccl5 (RANTES) as measured by qPCR (Fig 2A). This was in stark contrast to the γ134.5 null virus, which robustly induced the transcript expression of those genes, suggesting that the γ134.5 protein acts to dampen RIG-I-dependent innate immune responses. Importantly, in infected Rig-I−/− MEFs, viral induction of antiviral genes was greatly diminished, which attests a critical role of RIG-I in HSV-1 sensing as previously shown [15,16,40]. We further confirmed that a recombinant HSV, in which the γ134.5 gene was restored, behaved like wild type virus, ruling out the possibility that the observed phenotypes were due to an irrelevant mutation(s) elsewhere in the virus genome (S2 Fig). To assess whether γ134.5 functioned similarly in human cells, we determined cytokine expression in human lung fibroblasts infected with either wild type HSV-1 or the γ134.5 null virus (Fig 3A and 3B). Albeit with a different magnitude, the γ134.5 null virus readily induced expression of IFN-β, Ifit1, Ifit2 (Isg54) and Ccl5 (RANTES), relative to the wild type virus. RIG-I depletion by shRNA profoundly impaired such response to the HSV-1 variants. These results suggested that γ134.5 dampens the antiviral response mediated by RIG-I.
To verify an effect of γ134.5 on RIG-I signaling, we examined IRF3 phosphorylation, a hallmark of innate immune activation [1,41]. In Rig-I+/+ MEFs the γ134.5 null virus, but not wild type virus, readily induced the phosphorylation of IRF3 (Fig 2B). Although viral infectivity, as measured by ICP27 expression, was comparable, phosphorylation of IRF3 occurred only with the virus devoid of γ134.5 expression. The recombinant HSV-1 with repaired γ134.5 inhibited IRF3 phosphorylation similarly to wild type HSV-1 (S2 Fig). In Rig-I−/− MEFs virus-induced phosphorylation of IRF3 was abolished, further indicating a requirement of RIG-I in activating IRF3 during HSV-1 infection (Figs 2B and S2). Infection by the γ134.5 null virus, but not wild type virus, also readily triggered IRF3 phosphorylation in human lung fibroblasts (Fig 3C).

Taken together, these data show that the γ134.5 gene product functions as a previously unrecognized herpesviral inhibitor of RIG-I-induced innate immune signaling.

To determine whether γ134.5 interacts with RIG-I, we performed immunoprecipitation using an anti-RIG-I antibody (Fig 4A). We found that γ134.5 was precipitated with endogenous RIG-I in cells infected with wild type virus. Neither RIG-I nor γ134.5 was precipitated by control IgG. The γ134.5-RIG-I interaction was further verified in reciprocal immunoprecipitation with an anti-γ134.5 antibody (Fig 4B). To determine whether γ134.5 can bind RIG-I in the absence of other HSV proteins, we tested this interaction in 293T cells co-expressing Flag-γ134.5 or Flag-mCherry (control) together with Myc-RIG-I. As shown in Fig 4C, HSV-1 γ134.5, but not irrelevant mCherry, precipitated with Myc-RIG-I by IP with anti-Myc antibody. Conversely, RIG-I was specifically precipitated with γ134.5 by IP with anti-Flag antibody (Fig 4D). Moreover, γ134.5 interacted with the 2CARD domain of RIG-I and inhibited...
CARD-mediated IFN-β activation (S3 Fig). Deletion of the N- or C-terminal domain from γ134.5 abrogated its ability to interact with RIG-I and inhibit RIG-I signaling (S4 Fig). These observations strongly suggest that the γ134.5 protein inhibits cytosolic RNA sensing by targeting RIG-I in HSV-1 infection.

The γ134.5 protein blocks the mitochondrial translocation of RIG-I

To initiate antiviral immunity, RIG-I undergoes K63-linked ubiquitination by the E3 ligase tripartite motif-containing protein (TRIM25) and subsequently moves from the cytoplasm to mitochondria [1]. We noted that Sendai virus (SeV) effectively induced K63-linked ubiquitination of RIG-I ectopically expressed in 293T cells. Whereas influenza A virus NS1, a viral TRIM25 antagonist [42], potently diminished the K63-linked ubiquitination of RIG-I, HSV-1 γ134.5 exhibited little inhibitory effect on RIG-I polyubiquitination (Fig 5A and 5B). Congruently, the γ134.5 protein did not interrupt the interaction of TRIM25 and RIG-I (Fig 5C), suggesting a different mechanism is in operation. To test this, we examined the subcellular localization of RIG-I by fractionation analysis. In uninfected control 293T cells, RIG-I was seen primarily in the cytoplasm, as expected (Fig 6A). SeV infection markedly increased the abundance of RIG-I at the mitochondria; however, overexpression of γ134.5 substantially reduced the abundance of RIG-I in the mitochondrial fraction, which correlated with reduced IFN-promoter activation (Fig 6B). These results demonstrate that the γ134.5 protein interrupts the translocation of RIG-I from the cytoplasm to the mitochondria induced by RNA virus infection.
We next analyzed the cytosol-to-mitochondria re-localization of RIG-I in HSV-1-infected cells. RIG-I predominantly localized to the cytoplasmic fraction in mock-infected MEF cells (Fig 6C). Infection with the γ134.5 null virus drastically increased the abundance of RIG-I in the mitochondrial fraction. However, this increase was not detectable in wild type HSV-1 infected cells. Taken in combination, these results show that the γ134.5 protein prevents the mitochondrial translocation of RIG-I during HSV-1 infection.

HSV-1 γ134.5 prevents assembly of RIG-I and 14-3-3ε into a functional translocation complex

Cellular 14-3-3 proteins are essential components of cytosolic RNA sensing machineries [8,43]. In response to RNA virus infections, 14-3-3ε forms a complex with RIG-I to facilitate its mitochondrial translocation, activating downstream signaling. To further probe the mechanism of γ134.5 action, we assessed the effect of γ134.5 on RIG-I-14-3-3ε complex formation.
Myc-RIG-I detectably bound to endogenous 14-3-3ε in mock-infected cells, and infection with SeV enhanced such interaction (Fig 7A). The weaker band in the sample with vector co-transfection likely reflected non-specific binding. However, the presence of γ134.5 inhibited the binding of RIG-I to 14-3-3ε, as did dengue NS3, a viral antagonist of 14-3-3ε [44]. Interestingly, dengue NS3 bound to 14-3-3ε whereas γ134.5 failed to do so (Fig 7B). We reasoned that the γ134.5 protein may specifically target RIG-I, which prevents its assembly into the 14-3-3 complex.
translocation complex. To further test this, we analyzed 14-3-3ε-RIG-I binding in HSV-1-infected cells. As illustrated in Fig 7C, only a small amount of 14-3-3ε was precipitated with RIG-I in mock infected cells; however, infection with the γ134.5 null virus increased the amount of 14-3-3ε that co-precipitated with RIG-I. Crucially, infection with wild type HSV-1 nearly eliminated the binding of 14-3-3ε to RIG-I, which coincided with γ34.5 bound to RIG-I.

To determine the consequence of γ134.5 expression on downstream signaling, we assessed IRF3 activation with respect to the distribution of 14-3-3ε and RIG-I (Fig 7D). We observed
Fig 7. The γ₁34.5 protein precludes formation of the RIG-I-14-3-3ε complex required for mitochondrial translocation and IRF3 activation. (A) The γ₁34.5 protein prevents the interaction of RIG-I and 14-3-3ε. HEK-293T cells were transfected with Myc-RIG-I together with vector plasmid or Flag-γ₁34.5 or lag-Ns3-pro (DENV). At 24 h posttransfection, cells were treated with SeV (100HA/ml) for 24 h. Whole-cell lysates (WCLs) were subjected to immunoprecipitation (IP) with anti-Myc antibody. Precipitated proteins and WCLs were probed with antibodies against Flag, Myc, 14-3-3ε and β-actin. (B) The γ₁34.5 protein does not interact with 14-3-3ε. HEK-293T cells were cotransfected with Myc-14-3-3ε along with vector plasmids, Flag-mCherry, Flag-γ₁34.5 and Flag-Ns3-pro (DENV) for 36 h. Cells were then harvested and subjected to immunoprecipitation (IP) with anti-Myc antibody. Precipitated proteins and WCLs were probed with antibodies against Flag, Myc, and β-actin. (C) Inhibition of the RIG-I-14-3-3ε complex formation by HSV-1 requires γ₁34.5. MEFs were infected with wild type HSV-1 or Δγ₁34.5 (10 pfu/cell). At 8 h postinfection, cells were processed for immuno precipitation (IP) with anti-RIG-I antibody. Whole-cell lysates and precipitated proteins were probed with antibodies against RIG-I, 14-3-3ε, γ₁34.5, ICP27 and β-actin. (D) Block of RIG-I mitochondrial translocation by γ₁34.5 inhibits IRF3 phosphorylation. MEFs were infected with wild type HSV-1 or Δγ₁34.5 (10 pfu/cell). At 8h postinfection, cells were harvested for cytoplasmic and mitochondrial fractionation. Samples were processed for Western analysis with antibodies against 14-3-3ε, RIG-I, LDHA, COX IV MAVS, phosphorylated IRF3, IRF3, ICP27, γ₁34.5 and β-actin. The data are representative of results from three independent experiments.

https://doi.org/10.1371/journal.ppat.1009446.g007
that in mock-infected cells, RIG-I and 14-3-3ε were predominantly localized to the cytoplasm. On the other hand, MAVS was seen at the mitochondria, as expected. Infection with the γ34.5 null virus significantly increased the levels of 14-3-3ε and RIG-I at the mitochondria. However, this was not detectable with wild type virus, indicative of a block in mitochondrial translocation of RIG-I. Inhibition of RIG-I mitochondrial translocation also occurred upon ectopic expression of γ34.5 (S5 Fig), indicating that γ34.5 is directly responsible for this effect. Further analysis showed that unlike wild type HSV-1, the γ34.5 null virus induced phosphorylation of IRF3 (Fig 7D). Thus, the γ34.5 protein functionally disengaged RIG-I from 14-3-3ε to halt downstream signaling. This demonstrates that HSV-1 γ34.5 specifically interrupts a key step of RIG-I activation.

The RIG-I-γ34.5 interaction affects viral growth

Lastly, we assessed the impact of the RIG-I-γ34.5 interaction on viral growth. Fig 8A shows that wild type HSV-1 replicated robustly in both Rig-I+/+ and Rig-I−/− MEF cells, with titers reaching 2 x 10^6 and 4 x 10^6 pfu/ml, respectively. In contrast, the γ34.5 null virus replicated poorly in Rig-I+/+ MEF cells, with a titer of 2 x 10^2 pfu/ml. The growth defect of the γ34.5 null virus was dramatically restored in Rig-I−/− MEF cells (1 x 10^4 pfu/ml). We further examined the kinetics of viral growth (Fig 8B). In Rig-I+/+ MEF cells, wild type virus grew steadily as infection progressed, with a titer increasing to 1 x 10^6 pfu/ml at 48 h post-infection. However, the
\( \gamma_134.5 \) null mutant barely replicated in Rig-I\(^{+/+} \) cells throughout infection, with a titer of \(< 1 \times 10^2 \) pfu/ml. In Rig-I\(^{-/-} \) cells, both viruses replicated more efficiently than each virus did in Rig-I\(^{+/+} \) cells, with a faster growth kinetics. Similarly, knockdown of RIG-I by shRNA enhanced HSV replication in human lung fibroblasts in the absence \( \gamma_134.5 \) (Fig 8C and 8D). In contrast, virus replication was comparable in the presence and absence of the related RNA sensor MDA5 (S6 Fig). Collectively, these results demonstrate that RIG-I functions to limit HSV-1 replication, where the \( \gamma_134.5 \) protein serves to overcome the RIG-I-mediated virus restriction.

**Discussion**

Productive herpesvirus infection involves viral blockade of translation arrest by the dsRNA-dependent protein kinase, PKR [26,45–47]. Whether and how herpesviruses interact with the networks of cytosolic RNA sensors has been unresolved. Here we identified a previously unrecognized mechanism by which HSV-1 inhibits cytosolic RNA recognition by RIG-I. This activity is dependent on the virulence factor \( \gamma_134.5 \), which prevents assembly of RIG-I and 14-3-3\( \varepsilon \) into a ‘translocon’ complex, thereby impairing subsequent IRF3 phosphorylation and antiviral immunity. This work further underscores the importance of RIG-I in HSV-1 restriction [15,16,40].

As a large DNA virus, HSV-1 replication proceeds temporally, generating various virus- and host-derived stimulatory RNA species during the course of infection [15,17] that likely trigger several RNA sensing pathways simultaneously or sequentially. First, onset of HSV DNA replication is thought to activate PKR via dsRNA and shuts off protein synthesis [19]. Yet, viral \( \gamma_134.5 \), in cooperation with Us11, functionally inhibits PKR at discrete phases of HSV infection [48]. This involves dephosphorylation of the eukaryotic translation initiation factor eIF2 alpha by \( \gamma_134.5 \), which facilitates neuroinvasion in vivo [26,49]. Published work also indicates that herpesviruses instigate RIG-I through RNA polymerase III, a distinct pathway to initiate antiviral immunity [16,50]. HSV-1 infection causes translocation of host 5S ribosomal pseudogene transcripts (in particular RNA5SP141; also generated by RNA polymerase III) from the nucleus to the cytoplasm, and their subsequent unmasking by HSV-1-mediated depletion of RNA5SP141-binding proteins leads to activation of RIG-I [15]. RIG-I activation imposes another barrier to HSV-1 which would necessitate the immune-evasive actions of one or more viral genes to facilitate infection. As \( \gamma_134.5 \) is expressed early as well as late in infection [51–53], it may serve to control different RNA sensing machineries, which ensures the progression of HSV-1 replication.

We recently reported that the \( \gamma_134.5 \) protein interferes with the DNA sensing pathway through STING inactivation [34]. STING acts downstream of several DNA sensors, including cyclic GAMP synthase (cGAS), IFI16 and DDX41 that detect and limit HSV infection [36,54–56]. HSV \( \gamma_134.5 \) directly targets STING, and this interaction depends on the N-terminal domain of \( \gamma_134.5 \) [34]. This is different from its regulation of RIG-I, where full-length \( \gamma_134.5 \) is required for RIG-I antagonism as indicated by our data that showed that deletion of either the N-terminal or C-terminal domain of \( \gamma_134.5 \) abolished its activity against RIG-I. This suggests that the \( \gamma_134.5 \) protein functions to regulate two major signaling proteins in innate sensing (RIG-I and STING) using distinct interacting modes. In this context, it is notable that crossstalk between RIG-I and STING has been reported. For example, RIG-I activation by synthetic or viral agonists induces STING expression [57]. Conversely, STING deficiency leads to diminished IFN production in response to dsRNA or RNA virus infection [54,58]. Upregulated RIG-I can also participate in STING degradation [59]. Furthermore, temporally distinct roles have been reported for cGAS and RIG-I in the sensing of HSV-1 infection and subsequent cytokine induction [15]. Thus, a complex interplay between RIG-I and STING exists, and how
γ134.5 coordinately controls these two antiviral pathways throughout the HSV life cycle is an important question that awaits further investigation. Considering host selective pressures, our results suggest that the γ134.5 gene of HSV-1 may have evolved to cope with RIG-I in addition to PKR and STING. This model may explain, at least in part, why the γ134.5 protein functions as an HSV virulence factor in vivo [60], which warrants further investigation.

The mechanisms of RIG-I regulation are under intensive investigation [1,2]. Accumulating studies show that herpesviruses activate RIG-I via both viral and host-derived RNAs [10–12,15,16]. The mechanism by which HSV-1 γ134.5 inactivates RIG-I has been unknown. We found that HSV-1 γ134.5 displayed no inhibitory effect on the K63-linked ubiquitination of RIG-I mediated by TRIM25, an essential step in RIG-I activation [1,2]. Instead, γ134.5 prevented the assembly of the RIG-I-14-3-3ε complex and its re-localization from the cytoplasm to the mitochondria. This illustrates a powerful mechanism by which HSV-1 avoids MAVS activation, IRF3 phosphorylation and subsequent cytokine expression. As intact γ134.5 is required to interact with the CARDs of RIG-I, we infer that γ134.5 may compete with 14-3-3ε for the binding site on RIG-I. Alternatively, HSV-1 γ134.5 may alter the conformation of RIG-I that is required for access by 14-3-3ε, which then halts mitochondrial translocation of RIG-I. We propose that while RNA ligands induce conformational changes and posttranslational modifications of RIG-I, γ134.5 serves to selectively disable the cytosol-to-mitochondria translocation of RIG-I, which ultimately inhibits immune activation.

Our work reveals that the γ134.5-RIG-I interaction influences HSV-1 replication. In the presence of RIG-I, wild type virus replicated efficiently whereas deletion of the γ134.5 gene crippled viral replication. This is linked to the ability of γ134.5 to block the mitochondrial translocation of RIG-I, which phenotypically resembles the antagonistic activity by the NS3 proteins of dengue and Zika viruses [44,61]. Unlike the flavivirus NS3 proteins, HSV-1 γ134.5 uniquely targets RIG-I instead of 14-3-3. Many other RNA viruses perturb the RIG-I signaling pathway [62]. For example, influenza A virus NS1 inhibits the K63-linked ubiquitination of RIG-I mediated by TRIM25 [42]. The NS3/4A protease of hepatitis C virus cleaves MAVS [63,64] and also abolishes RIG-I ubiquitination by Riplet [65], while the 3C proteins from certain picornaviruses cleave RIG-I [66]. Other studies suggest that the BPLF1 protein of Epstein-Barr virus (EBV) inhibits the K63-linked ubiquitination of RIG-I through recruitment of 14-3-3 to sequester and inactivate MAVS through itself [67]. HSV-1 UL37 deaminates and inhibits RIG-I sensing [68,69]. On the other hand, US11 of HSV-1 impairs RIG-I via PACT inactivation [70,71]. Additional modulation of RIG-I by γ134.5 indicates a complex regulatory circuit that might be relevant to temporal replication of herpesviruses. Strikingly, genetic ablation of RIG-I, but not MDA5, markedly reversed the HSV-1 growth defect in the absence of γ134.5. Such specificity may reflect the requirement of a separate HSV function for restricting MDA5, or it may imply that MDA5 is not required for the restriction of HSV-1 replication. Further work is required to clarify this issue.

It is noteworthy that inborn errors in type I IFN-mediated immunity contribute to HSV encephalitis in humans. This is illustrated by mutations in TANK, IFNα, or TLR3 in individual patients [72–75]. Consistently, in murine HSV encephalitis models, deficiency in MAVS or in TRIF that is a TLR3 adaptor, increases mortality rates [76]. It is tempting to speculate that inhibition of RIG-I by γ134.5 may favor HSV-mediated pathology. Further development of relevant in vivo models will be required to address this question. Moreover, genetically modified HSV that lacks γ134.5 is avirulent and approved for melanoma therapy in humans [21,24]. Recent work further suggested that its combination with immune checkpoint blockade enhances therapeutic efficacy [23]. Therefore, it would be intriguing to investigate whether RIG-I activation by γ134.5 null oncolytic HSV primes antitumor
immunity. Further characterization may lead to the development of next generation therapeutic agents.

Materials and methods

Cells and viruses

Vero, HEK-293T, Human lung embryonic (HEL) fibroblasts cells were obtained from the American Type Culture Collection. RIG-I (Ddx58) wild type (Rig-I\(^{+/+}\)) MEFs and RIG-I knockout (Rig-I\(^{-/-}\)) MEFs, MDA5 (Ifih1) wild type (Mda5\(^{+/+}\)) MEFs and MDA5 knockout (Mda5\(^{-/-}\)) were described previously [77]. HEL stably expressed Non-Target shRNA (shCtrl) or RIG-I target shRNA (shRIG-I) were selected with puromycin (sc-205821, Santa Cruz Biotechnology) at the concentration 3\(\mu\)g/ml. Cells were propagated in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 5% or 10% fetal bovine serum. HSV-1(F) is a prototype HSV-1 strain used in this study [78]. In recombinant virus \(\Delta\gamma_{134.5}\), a 1-kb fragment from the coding region of the \(\gamma_{134.5}\) gene was deleted [60]. In recombinant virus HSV-1(R), the deleted coding region of \(\gamma_{134.5}\) was repaired to restore the wild type \(\gamma_{134.5}\) gene [60]. Preparation of viral stock and titration of infectivity were carried out with Vero cells.

Antibodies

Mouse anti-\(\beta\)-actin (A5316) and anti-Flag-HRP antibodies (A8592) were purchased from Sigma-Aldrich. Anti-Myc-horseradish peroxidase (HRP) antibody (#2040), anti-HA-HRP antibody (#2999), rabbit anti-IRF-3 (#11904), rabbit anti-pIRF-3 (#4947), rabbit anti-Flag (#14793), rabbit anti-LDHA (#3582), rabbit anti-COX IV (#4844), anti-rabbit IgG-HRP-linked antibody (#7074), anti-mouse IgG-HRP-linked antibody (#7076), normal rabbit IgG (#2729) were bought from Cell-Signaling Technologies. Mouse anti-Myc antibody (sc-40), mouse anti-HA antibody (sc-7392), mouse anti-RIG-I (sc-376845), mouse anti-14-3-3\(\epsilon\)-horseradish peroxidase (HRP) antibody (sc-23957 HRP), mouse anti-V5 antibody (sc-81594), mouse anti-MAVS (sc-365334), normal mouse IgG (sc-2025) were purchased from Santa Cruz Biotechnology. Mouse anti-HSV ICP27 antibody (P1113) was purchased from Virusys. Anti-\(\gamma_{134.5}\) and NS1 antibodies were described previously [79,80].

Plasmids and reporter assays

pLKO.1-puro Non-Target shRNA Control Plasmid and pLKO.1-puro RIG-I Target shRNA Plasmid were purchased from Sigma-Aldrich. The lentivirus package plasmids pCMV-VSV-G, pMDLg/pRRE, and pRSV-REV were previously described [81]. Flag-RIG-I, Myc-RIG-I, Myc-RIG-I-2CARDs, Myc-14-3-3\(\epsilon\), Flag-NS3-Pro (DENV), V5-TRIM25, HA-Ub (K63 only), Flag-\(\gamma_{134.5}\), Flag-N159, Flag-\(\Delta N146\), Flag-mCherry and pCAGGS-NS1 were described previously [6,44,53,82–84]. For luciferase reporter assays, HEK-293T cells grown in 24-well plates were transfected with a luciferase reporter plasmid IFN-\(\beta\)-Luc, and pRL-TK (Promega), together with the indicated expression plasmid or an empty vector using Lipofectamine 3000 (Invitrogen) according to the manufactural instruction. At 48 h posttransfection, cells were harvested for Dual-Luciferase reporter assay system [14]. In Sendai virus infection experiments, cells were stimulated with the virus (100 HA/ml) for 24 h.

Virus infection assay

Cells were infected with viruses at the indicated multiplicity of infection. After adsorption for 2 h, the monolayers were overlaid with DMEM supplemental with 1% FBS and incubated at...
37°C. For viral titer determination, samples were harvested at 48 hours postinfection and viruses, released by three cycles of freezing and thawing, were titrated on Vero cells [53].

**RNA sequencing and data analysis**

Total RNA from Mock, HSV-1(F) and Δγ134.5 infected MEFs was extracted using a RNeasy Plus mini kit (Qiagen) and then subjected to RNA-deep sequencing (RNA-seq) analysis (Novogene). Sequencing libraries were generated using NEBNext Ultra RNA Library Prep Kit for Illumina following the manufacturer’s recommendations, and index codes were added to attribute sequences to each sample. The clustering of the index-coded samples was performed on a cBot Cluster Generation System using TruSeq PE Cluster Kit v3-cBot-HS (Illumina). After cluster generation, the library preparations were sequenced on an Illumina HiSeq platform, and 125 bp/150 bp paired-end reads were generated.

Raw reads were aligned to the mouse reference genome in a splice-aware manner using the STAR aligner [85]. ENSEMBL gene and transcript annotations, which include non-coding RNAs in addition to mRNAs, were used. With Feature Counts [86], gene expression was first quantified as raw read counts and then normalized to reads-per-million for direct comparison between samples. Pair-wise differential expression statistics (fold-change and p-value) were computed using edgeR [87,88]. p-values were adjusted for multiple testing using the false discovery rate (FDR) correction of Benjamini and Hochberg [89].

To perform GSEA analysis on RNA-seq datasets, the log fold changes of all genes in edgeR result output were used to generate a ranked list for GSEA preranked analysis using the Molecular Signatures Database v5.2 (H: hallmark gene sets) [35]. Specifically, the differences in log2 fold changes of all genes in virus-infected cells relative to the mock group were used to generate the ranked list. Enriched gene sets ranked by GSEA normalized enrichment score (NES) were visualized using ggplot2 package in R. Gene sets with a nominal p value < 0.05 and false discovery rate (FDR) < 0.25 were defined as significantly enriched. Heat maps were produced from the primary data (the normalized expression value) using the R package pheatmap v1.0.8.

**Quantitative real-time PCR assay**

Total RNA was harvested from cells using a RNeasy Plus mini kit (Qiagen). Genomic DNA was eliminated using gDNA Eliminator columns. cDNA was synthesized using a high-capacity cDNA reverse transcription kit (Applied Biosystems). Quantitative real-time PCR was performed using an Applied Biosystems ABI Prism 7900HT instrument with SYBR green master mix (Applied Biosystems). Gene expression levels were normalized to that of endogenous control 18S rRNA. Relative gene expression was determined as described previously [90]. All primers were listed in S1 Table.

**Western blot**

Cells were harvested, washed with phosphate-buffered saline (PBS), and lysed as described previously [91]. Samples were then subjected to electrophoresis on denaturing polyacrylamide gels, transferred to Polyvinylidene difluoride (PVDF) membranes, and reacted with indicated antibodies [83].

**Immunoprecipitation and ubiquitination analysis**

To detect protein interactions, immunoprecipitation was performed as described previously [91]. Briefly, cells were lysed, and cell extracts were incubated with the indicated antibodies
and agarose conjugated with protein A/G (sc-2003, Santa Cruz Biotechnology) at 4˚C. The beads were washed three times with wash buffer (50 mm Tris-HCl, pH 7.4, 150 mm NaCl, 5 mm EDTA, 0.1% Triton X-100, and protease inhibitor mixture). The samples were then subjected to immunoblotting analysis. For detection of RIG-I ubiquitination, cells were lysed with lysis buffer (1% SDS, 150 mM NaCl, 10 mM Tris-HCl, pH 8.0) with 2mM sodium orthovanadate, 50 mM sodium fluoride, and protease inhibitors. Samples were precipitated and washed RIPA buffer containing 2M urea to remove nonspecific binding of other ubiquitinated proteins.

**Lentiviral transduction**

pLKO.1 Puro RIG-I Target shRNA Plasmid and pLKO.1 Puro Non-Target shRNA Control Plasmid (negative control) were purchased from shRNA (Sigma-Aldrich). The lentivirus was produced after transfection of shRNA plasmid together with package plasmids (pCMV-VSV-G, pMDLg/pRRE, and pRSV-REV) in HEK-293T cells. HEL were then infected with the collected lentivirus. At 16 h after infection, the medium was replaced with fresh medium. At 3 days after infection, the cells were selected by 3μg/ml puromycin (sc-205821, Santa-Cruz Biotechnology). Experiments were performed within 2 weeks after lentiviral transduction.

**Mitochondrial fractionation analysis**

MEFs were mock infected or infected with wild type HSV-1(F) and Δγ134.5. At 8 h postinfection, the cells were harvested to prepare cytoplasmic and mitochondrial fractions using an EzSubcell Fraction Kit (ATTO, Tokyo, Japan). Samples were then analyzed by immunoblotting. For HEK-293T analysis, cells were transfected with Flag-γ134.5 for 24 h, followed by treatment with SeV at the 100HA/ml for additional 24h. And the cells were harvested for cell fractionation analysis.

**Statistical analysis**

All data were presented as means ± SD and analyzed using GraphPad Prism software (version 6). One-way ANOVA with Dunnett’s multiple comparisons or an unpaired two-tailed Student’s t test was used as indicated in the legends. For the graphs, data were in general three biological replicates and reproduced in independent experiments as indicated in the legends.

**Supporting information**

**S1 Fig. Pathway analysis with GSEA.** GSEA of RNA-seq data showing significantly enriched hallmark signatures of IFN-α (A) and IFN-γ (B) pathways in virus-infected cells. The plots compare enrichment scores between cells infected with the γ134.5 null virus and wild type HSV-1 as described in MATERIALS AND METHODS.

**(TIF)**

**S2 Fig. Inhibition of RIG-I dependent antiviral responses by the γ134.5 gene product is not due to an irrelevant mutation(s) elsewhere in the HSV-1 genome.** (A) Effects of γ134.5 on antiviral gene expression in Rig-1+/+ or Rig-1−/− MEF cells. Cells, infected with HSV-1, Δγ134.5 or its repair virus HSV-1(R) (5 pfu/cell) for 8 h, were analyzed for transcript levels of IFN-β, Ifit1, Ifit2, and Ccl5 by quantitative PCR analysis. The data were statistically analyzed by one-way ANOVA (**, P < 0.01), with standard deviations (SD) (n = 3). (B) Effects of γ134.5 on IRF3 phosphorylation in Rig-1+/+ or Rig-1−/− MEF cells. Cells were infected as described in panel A and processed for western blot analysis with antibodies against p-IRF3, IRF3, ICP27, γ134.5, RIG-I and β-actin. The experimental data are representative of results from three
independent experiments.

S3 Fig. The γ134.5 protein interacts with RIG-I CARD domain and inhibits RIG-I induced IFN-β promoter activity. (A) HSV-1 γ134.5 binds the RIG-I CARD domain. HEK-293T cells were transfected with Myc-RIG-I-2CARDs together with empty vector (Vec) or Flag-γ134.5 or Flag-mCherry for 36 h. Whole-cell lysates (WCLs) were subjected to immunoprecipitation (IP) with anti-Myc antibody. Precipitated proteins and whole-cell lysates (WCL) were probed with antibodies against Flag, Myc, and β-actin. (B) The γ134.5 protein inhibits IFN-β promoter activation by RIG-I. HEK-293T cells were co-transfected with Myc-RIG-I-2CARDs (100 ng), pIFN-β-luc (50 ng) and pRL-TK (10 ng) along with the Vector (400ng) or Flag-γ134.5(400ng) or pCAGGS-NS1(400ng). At 48 h after transfection, luciferase activities were determined. (C) The γ134.5 protein inhibits RIG-I in a dose dependent manner. HEK-293T cells were co-transfected with different doses of Flag-γ134.5 and harvested for luciferase assays as described in (B). Results are expressed as fold activation relative to the empty vector control with SD (n = 3) and assessed by one-way ANOVA (**, P < 0.01) for (A) and (B). The experimental data are representative of results from three independent experiments.

S4 Fig. Intact γ134.5 is required to interact with and inhibit RIG-I. (A) Schematic depiction of the γ134.5 variants. Numbers indicate amino acid positions. (B) and (C) The γ134.5 protein interacts with RIG-I in the absence of other viral proteins. HEK-293T cells were transfected with plasmids encoding Myc-RIG-I together with empty vector (Vec) or Flag-tagged γ134.5 variants (γ134.5, ΔN146 and N159) for 36 h. Whole-cell lysates (WCLs) were subjected to immunoprecipitation (IP) with anti-Myc (B) or anti-Flag (C) antibody. Precipitated proteins and whole-cell lysates (WCL) were probed with antibodies against Flag, Myc, and β-actin. (D) Effects of γ134.5 variants on IFN-β promoter activation by the RIG-I-2CARDs domain. HEK-293T cells were co-transfected with Myc-RIG-I-2CARDs (100 ng), pIFN-β-luc (50 ng) and pRL-TK (10 ng) along with the Vector, Flag-γ134.5 or its mutants (Flag-ΔN146 and Flag-N159). Cells were harvested for luciferase assays at 48 h after transfection. Results are expressed as fold activation relative to the empty vector control with SD (n = 3) and assessed by one-way ANOVA (**, P < 0.01). The experimental data are representative of results from three independent experiments.

S5 Fig. The γ134.5 protein inhibits RIG-I-14-3-3ε complex translocation to the mitochondria. The influence of γ134.5 gene on RIG-I and 14-3-3ε mitochondrial localization after SeV stimulation. HEK-293T cells were transfected with Flag-γ134.5 for 24 h, which was followed by SeV stimulation at the 100 HA/ml for additional 24 h. Cells were harvested and analyzed for the RIG-I and 14-3-3ε in the cytoplasmic and mitochondrial fractions. The experimental data are representative of results from three independent experiments.

S6 Fig. MDA5 is not associated with the replication of γ134.5 null mutant HSV-1. (A) Viral replication in Mda5+/+ or Mda5−/− MEFs. Cells were infected with wild-type HSV-1 and the γ134.5 deletion virus (Δγ134.5) at a MOI 0.01. At 48 h postinfection, the total virus yields were determined on Vero cells using plaque assay. (B) Kinetics of viral growth in Mda5+/+ or Mda5−/− MEFs. Viral infection was performed as described in panel (A) and viral yields were measured at indicated time points. The data are representative of results from three experiments with triplicate samples. Differences between the selected groups were statistically
assessed by one-way ANOVA for (A) or a two-tailed Student’s t test for (B) (**, P < 0.01).

S1 Table. Primers used for RT-PCR.

Acknowledgments
We thank Donna MacDuff and Zhengdeng Lei at Research Resources Center of UIC for assistance and technical support.

Author Contributions
Conceptualization: Xing Liu, Yijie Ma, Bin He.

Formal analysis: Xing Liu, Yijie Ma, Michaela U. Gack.

Funding acquisition: Michaela U. Gack, Michael Gale, Jr, Bin He.

Investigation: Xing Liu, Yijie Ma.

Methodology: Xing Liu, Yijie Ma.

Project administration: Bin He.

Resources: Xing Liu, Yijie Ma, Kathleen Voss, Michiel van Gent, Ying Kai Chan, Michaela U. Gack, Michael Gale, Jr, Bin He.

Supervision: Bin He.

Validation: Xing Liu.

Visualization: Xing Liu, Yijie Ma.

Writing – original draft: Xing Liu, Bin He.

Writing – review & editing: Xing Liu, Yijie Ma, Michiel van Gent, Ying Kai Chan, Michaela U. Gack, Michael Gale, Jr, Bin He.

References
1. Chow KT, Gale M Jr., Loo YM. RIG-I and other RNA sensors in antiviral immunity. Annu Rev Immunol. 2018; 36:667–94. https://doi.org/10.1146/annurev-immunol-042617-053309 PMID: 29677479
2. Rehwinkel J, Gack MU. RIG-I-like receptors: their regulation and roles in RNA sensing. Nat Rev Immunol. 2020. https://doi.org/10.1038/s41577-020-0288-3 PMID: 32203325
3. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol. 2004; 5(7):730–7. https://doi.org/10.1038/ni1087 PMID: 15208624
4. Oshiumi H, Matsumoto M, Seya T. Ubiquitin-mediated modulation of the cytoplasmic viral RNA sensor RIG-I. J Biochem. 2012; 151(1):5–11. https://doi.org/10.1093/jb/mvr111 PMID: 21890623
5. Wies E, Wang MK, Maharaj NP, Chen K, Zhou S, Finberg RW, et al. Dephosphorylation of the RNA sensors RIG-I and MDA5 by the phosphatase PP1 is essential for innate immune signaling. Immunity. 2013; 38(3):437–49. https://doi.org/10.1016/j.immuni.2012.11.018 PMID: 23499489
6. Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L, et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature. 2007; 446(7138):916–20. https://doi.org/10.1038/ nature05732 PMID: 17392790
7. Oshiumi H, Miyashita M, Inoue N, Okabe M, Matsumoto M, Seya T. The ubiquitin ligase Riplet is essential for RIG-I-dependent innate immune responses to RNA virus infection. Cell Host Microbe. 2010; 8 (6):496–509. https://doi.org/10.1016/j.chom.2010.11.008 PMID: 21147464
8. Liu HM, Loo YM, Horner SM, Zornetzer GA, Katze MG, Gale M Jr., The mitochondrial targeting chaperone 14-3-3 epsilon regulates a RIG-I translocon that mediates membrane association and innate
antiviral immunity. Cell Host Microbe. 2012; 11(5):528–37. https://doi.org/10.1016/j.chom.2012.04.006 PMID: 22607805

9. Zhao Y, Karijolich J. Know thyself: RIG-I-like receptor sensing of DNA Virus infection. J Virol. 2019; 93(23). https://doi.org/10.1128/JVI.01085-19 PMID: 31511389

10. West JA, Wicks M, Gregory SM, Chugh P, Jacobs SR, Zhang Z, et al. An important role for mitochondrial antiviral signaling protein in the Kaposi’s sarcoma-associated herpesvirus life cycle. J Virol. 2014; 88(10):5778–87. https://doi.org/10.1128/JVI.03226-13 PMID: 24623417

11. Zhang Y, Dittmer DP, Mieczkowski PA, Host KM, Fusco WG, Duncan JA, et al. RIG-I detects Kaposi’s sarcoma-associated herpesvirus transcripts in a RNA polymerase III-independent manner. mBio. 2018; 9(4).

12. Zhao Y, Ye X, Dunker W, Song Y, Karijolich J. RIG-I-like receptor sensing of host RNAs facilitates the cell-intrinsic immune response to KSHV infection. Nat Commun. 2018; 9(1):4841. https://doi.org/10.1038/s41467-018-07314-7 PMID: 30451863

13. Samanta M, Iwakiri D, Kanda T, Imaizumi T, Takada K. EB virus-encoded RNAs are recognized by RIG-I and activate signaling to induce type I IFN. EMBO J. 2006; 25(18):4207–14. https://doi.org/10.1038/sj.emboj.7601314 PMID: 16946700

14. Samanta M, Iwakiri D, Takada K. Epstein-Barr virus-encoded small RNA induces IL-10 through RIG-I-mediated IRF-3 signaling. Oncogene. 2008; 27(30):4150–60. https://doi.org/10.1038/onc.2008.75 PMID: 18362887

15. Chiang JJ, Sparrer KMJ, van Gent M, Lassig C, Huang T, Osterrieder N, et al. Viral unmasking of cellular SS rRNA pseudogene transcripts induces RIG-I-mediated IFN production. Nat Immunol. 2018; 19(1):53–62. https://doi.org/10.1038/s41590-017-0005-y PMID: 29180807

16. Chiu YH, Macmillan JB, Chen ZJ. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell. 2009; 138(3):576–91. https://doi.org/10.1016/j.cell.2009.06.015 PMID: 19631370

17. Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet. 2001; 357(9267):1513–8. https://doi.org/10.1016/S0140-6736(00)04638-9 PMID: 11377626

18. Chou J, Roizman B. The herpes simplex virus 1 gene for ICP34.5, which maps in inverted repeats, is conserved in several limited-passage isolates but not in strain 17syn+. J Virol. 1990; 64(3):1014–20. https://doi.org/10.1128/JVI.64.3.1014-1020.1990 PMID: 2154589

19. Chou J, Roizman B. The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells. Proc Natl Acad Sci U S A. 1992; 89(8):3266–70. https://doi.org/10.1073/pnas.89.8.3266 PMID: 1313483

20. Taha MY, Clements GB, Brown SM. The herpes simplex virus type 2 (HG52) variant JH2604 has a 1488 bp deletion which eliminates neurovirulence in mice. J Gen Virol. 1989; 70(Pt 11):3073–8.

21. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015; 33(25):2780–8. https://doi.org/10.1200/JCO.2014.58.3377 PMID: 26014293

22. Streby KA, Geller JI, Currier MA, Warren PS, Racadio JM, Towbin AJ, et al. Intratumoral injection of HSV1716, an oncolytic herpes virus, ss safe and shows evidence of immune response and viral replication in young cancer patients. Clin Cancer Res. 2017; 23(14):3566–74. https://doi.org/10.1158/1078-0432.CCR-16-2900 PMID: 28495911

23. Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RH, Michielin O, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017; 170(6):1109–19 e10. https://doi.org/10.1016/j.cell.2017.08.027 PMID: 28886381

24. Raman SS, Hecht JR, Chan E. Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety. Immunotherapy. 2019; 11(8):705–23. https://doi.org/10.2217/imt-2019-0033 PMID: 31045646

25. Chou J, Chen JJ, Gross M, Roizman B. Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of herpes simplex virus 1. Proc Natl Acad Sci U S A. 1995; 92(23):10516–20. https://doi.org/10.1073/pnas.92.23.10516 PMID: 7479831

26. He B, Gross M, Roizman B. The γ134.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci U S A. 1997; 94(3):843–8. https://doi.org/10.1073/pnas.94.3.843 PMID: 9023344

27. Mohr I, Sternberg D, Ward S, Leib D, Mulvey M, Gluzman Y. A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely
28. Cassady KA, Bauer DF, Roth J, Chambers MR, Shoeb T, Coleman J, et al. Pre-clinical assessment of C134, a chimeric oncolytic herpes simplex virus, in mice and non-human primates. Mol Ther Oncolytics. 2017; 5:1–10. https://doi.org/10.1016/j.omto.2017.02.001 PMID: 28345027

29. Mao H, Rosenthal KS. Strain-dependent structural variants of herpes simplex virus type 1 ICP34.5 determine viral plaque size, efficiency of glycoprotein processing, and viral release and neuroinvasive disease potential. J Virol. 2003; 77(6):3409–17. https://doi.org/10.1128/JVI.77.6.3409-3417.2003 PMID: 12610116

30. Brown SM, MacLean AR, Aitken JD, Harland J. ICP34.5 influences herpes simplex virus type 1 maturation and egress from infected cells in vitro. J Gen Virol. 1994; 75(12):3679–86. https://doi.org/10.1099/0022-1317-75-12-3679 PMID: 7996163

31. Wu S, Pan S, Zhang L, Baines J, Roller R, Ames J, et al. Herpes simplex virus 1 induces phosphorylation and reorganization of lamin A/C through the gamma134.5 protein that facilitates nuclear egress. J Virol. 2016; 90(22):10414–22. https://doi.org/10.1128/JVI.01392-16 PMID: 27630226

32. Orvedahl A, Alexander D, Tallozcy Z, Sun Q, Wei Y, Zhang W, et al. HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein. Cell Host & Microbe. 2007; 1(1):23–35. https://doi.org/10.1016/j.chom.2006.12.001 PMID: 18005679

33. Alexander DE, Ward SL, Mizushima N, Levine B, Leib DA. Analysis of the role of autophagy in replication of herpes simplex virus in cell culture. J Virol. 2007; 81(22):12128–34. https://doi.org/10.1128/JVI.01356-07 PMID: 17855538

34. Pan S, Liu X, Ma Y, Cao Y, He B. Herpes simplex virus 1 γ134.5 protein inhibits STING activation that restricts viral replication. J Virol. 2018; 92(20). https://doi.org/10.1128/JVI.01015-18 PMID: 30045990

35. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545–50. https://doi.org/10.1073/pnas.0506580102 PMID: 16199517

36. Unterholzner L, Keating SE, Baran M, Horan KA, Jensen SB, Sharma S, et al. IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol. 2010; 11(11):997–1004. https://doi.org/10.1038/ni.1932 PMID: 20890285

37. Stavrou S, Blouch K, Kotla S, Bass A, Ross SR. Nucleic acid recognition orchestrates the anti-viral response to retroviruses. Cell Host Microbe. 2015; 17(4):478–88. https://doi.org/10.1016/j.chom.2015.02.021 PMID: 25816774

38. Nakaya Y, Lilue J, Stavrou S, Moran EA, Ross SR. AIM2-like receptors positively and negatively regulate the interferon response induced by cytosolic DNA. mBio. 2017; 8(4). https://doi.org/10.1128/mBio.00944-17 PMID: 28679751

39. Thapa RJ, Ingram JP, Ragan KB, Nogusa S, Boyd DF, Benitez AA, et al. DAI senses influenza A virus genomic RNA and activates RIPK3-dependent cell death. Cell Host Microbe. 2016; 20(5):674–81. https://doi.org/10.1016/j.chom.2016.09.014 PMID: 27746097

40. Rasmussen SB, Jensen SB, Nielsen C, Quartin E, Chen ZJ, et al. Herpes simplex virus infection is sensed by both Toll-like receptors and retinoic acid-inducible gene-like receptors, which synergize to induce type I interferon production. J Gen Virol. 2009; 90(1):74–8. https://doi.org/10.1099/vir.0.005389-0 PMID: 19088275

41. Streicher F, Jouvenet N. Stimulation of Innate Immunity by Host and Viral RNAs. Trends Immunol. 2019; 40(12):1134–48. https://doi.org/10.1016/j.it.2019.10.009 PMID: 31735513

42. Gack MU, Albrecht RA, Urano T, Inn KS, Huang IC, Camero E, et al. Influenza A virus N1S1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe. 2009; 5(5):439–49. https://doi.org/10.1016/j.chom.2009.04.006 PMID: 19454348

43. Lin JP, Fan YK, Liu HM. The 14–3–3eta chaperone protein promotes antiviral innate immunity via facilitating MDA5 oligomerization and intracellular redistribution. PLoS Pathog. 2019; 15(2):e1007582. https://doi.org/10.1371/journal.ppat.1007582 PMID: 30742689

44. Chan YK, Gack MU. A phosphomimetic-based mechanism of dengue virus to antagonize innate immunity. Nat Immunol. 2016; 17(5):523–30. https://doi.org/10.1038/ni.3393 PMID: 26998762

45. Carpenter KS, Espauro NM, Child SJ, Geballe AP. A single amino acid dictates protein kinase R susceptibility to unrelated viral antagonists. PLoS Pathog. 2016; 12(10):e1005966. https://doi.org/10.1371/journal.ppat.1005966 PMID: 27780231

46. Sharma NR, Majerciak V, Kruhlak MJ, Zheng ZM. KSHV inhibits stress granule formation by viral ORF57 blocking PKR activation. PLoS Pathog. 2017; 13(10):e1006677. https://doi.org/10.1371/journal.ppat.1006677 PMID: 29084250
48. Mulvey M, Poppers J, Stemberg D, Mohr I. Regulation of eIF2alpha phosphorylation by different functions that act during discrete phases in the herpes simplex virus type 1 life cycle. J Virol. 2003; 77(20):10917–28. https://doi.org/10.1128/jvi.77.20.10917-10928.2003 PMID: 14512542

49. Verpooten D, Feng Z, Valyi-Nagy T, Ma Y, Jin H, Yan Z, et al. Dephosphorylation of eIF2alpha mediated by the γ34.5 protein of herpes simplex virus 1 facilitates viral neuroinvasion. J Virol. 2009; 83(23):12626–30. https://doi.org/10.1128/JVI.01431-09 PMID: 19759130

50. Ablasser A, Bauernfeind F, Hartmann G, Latz E, Fitzgerald KA, Hornung V. RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol. 2009; 10(10):1065–72. https://doi.org/10.1038/ni.1779 PMID: 19609254

51. Chou J, Roizman B. The terminal sequence of the herpes simplex virus genome contains the promoter of a gene located in the repeat sequences of the L component. J Virol. 1986; 57(2):629–37. https://doi.org/10.1128/jvi.57.2.629-637.1986 PMID: 3003394

52. McKay EM, McVey B, Marsden HS, Brown SM, MacLean AR. The herpes simplex virus type 1 strain 17 open reading frame RL1 encodes a polypeptide of apparent Mr 37K equivalent to ICP34.5 of herpes simplex virus type 1 strain F. J Gen Virol. 1993; 74(Pt 11):2493–7. https://doi.org/10.1099/0022-1317-74-11-2493 PMID: 8245868

53. Verpooten D, Ma Y, Hou S, Yan Z, He B. Control of TANK-binding kinase 1-mediated signaling by the γ34.5 protein of herpes simplex virus 1. J Biol Chem. 2009; 284(2):1097–105. https://doi.org/10.1074/jbc.M805905200 PMID: 19010780

54. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008; 455(7213):674–8. https://doi.org/10.1038/nature07317 PMID: 18724357

55. Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science. 2013; 339(6121):786–91. https://doi.org/10.1126/science.1232458 PMID: 23258413

56. Zhang Z, Yuan B, Bao M, Lu N, Kim T, Liu YJ. The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. Nat Immunol. 2011; 12(10):959–65. https://doi.org/10.1038/ni.2091 PMID: 21892174

57. Liu Y, Goulet ML, Sze A, Hadj SB, Belgnaoui SM, Lababidi RR, et al. RIG-I-mediated STING upregulation restricts herpes simplex virus 1 infection. J Virol. 2016; 90(20):9406–19. https://doi.org/10.1128/JVI.00748-16 PMID: 27512060

58. Zhong B, Yang Y, Li S, Wang YY, Li Y, Diao F, et al. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity. 2008; 29(4):538–50. https://doi.org/10.1016/j.immuni.2008.09.003 PMID: 18818105

59. Wu X, Yang J, Na T, Zhang K, Davidoff AM, Yuan BZ, et al. RIG-I and IL-6 are negative-feedback regulators of STING induced by double-stranded DNA. PLoS One. 2017; 12(8):e0182961. https://doi.org/10.1371/journal.pone.0182961 PMID: 28806404

60. Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus 1 neurovirulence to gamma 34.5, a gene nonessential for growth in culture. Science. 1990; 250(4985):1262–6. https://doi.org/10.1126/science.2173860

61. Meyaen E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature. 2005; 437(7062):1167–72. https://doi.org/10.1038/nature04193 PMID: 16177806

62. Liu Y, Olagnier D, Lin R. Host and viral modulation of RIG-I-mediated antiviral immunity. Front Immunol. 2016; 7:662. https://doi.org/10.3389/fimmu.2016.00662 PMID: 28096803

63. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature. 2005; 437(7062):1167–72. https://doi.org/10.1038/nature04193 PMID: 16177806

64. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci U S A. 2005; 102(49):17717–22. https://doi.org/10.1073/pnas.0508531102 PMID: 16301520

65. Oshiumi H, Miyashita M, Matsumoto M, Seya T. A distinct role of Riplet-mediated K63-Linked polyubiquination of the RIG-I repressor domain in human antiviral innate immune responses. PLoS Pathog. 2013; 9(8):e1003533. https://doi.org/10.1371/journal.ppat.1003533 PMID: 23950712

66. Barral PM, Sarkar D, Fisher PB, Racaniello VR. RIG-I is cleaved during picornavirus infection. Virology. 2009; 391(2):171–6. https://doi.org/10.1016/j.virol.2009.06.045 PMID: 19628239
67. Inn KS, Lee SH, Rathbun JY, Wong LY, Toth Z, Machida K, et al. Inhibition of RIG-I-mediated signaling by Kaposi's sarcoma-associated herpesvirus-encoded deubiquitinase ORF64. J Virol. 2011; 85(20):10899–904. https://doi.org/10.1128/JVI.00960-11 PMID: 21835791

68. Gupta S, Yla-Anttila P, Callegari S, Tsai MH, Masucci MG. Herpesvirus deconjugases inhibit the IFN response by promoting TRIM25 autoubiquitination and functional inactivation of the RIG-I signalosome. PLoS Pathog. 2018; 14(1):e1006852. https://doi.org/10.1371/journal.ppat.1006852 PMID: 29357390

69. Zhao J, Zeng Y, Xu S, Chen J, Shen G, Yu C, et al. A viral deamidase targets the helicase domain of RIG-I to block RNA-induced activation. Cell Host Microbe. 2016; 20(6):770–84. https://doi.org/10.1016/j.chom.2016.10.011 PMID: 27866900

70. Kew C, Lui PY, Chan CP, Liu X, Au SW, Mohr I, et al. Suppression of PACT-induced type I interferon production by herpes simplex virus 1 Us11 protein. J Virol. 2013; 87(24):13141–9. https://doi.org/10.1128/JVI.02564-13 PMID: 24067967

71. Xing J, Wang S, Lin R, Mossman KL, Zheng C. Herpes simplex virus 1 tegument protein US11 down-modulates the RLR signaling pathway via direct interaction with RIG-I and MDA-5. J Virol. 2012; 86(7):3528–40. https://doi.org/10.1128/JVI.06713-11 PMID: 22301138

72. Herman M, Ciancanelli M, Ou YH, Lorenzo L, Klaudel-Dreiszler M, Pauwels E, et al. Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood. J Exp Med. 2012; 209(9):1567–82. https://doi.org/10.1084/jem.20111316 PMID: 22851595

73. Andersen LL, Mork N, Reinert LS, Kofod-Olsen E, Narita R, Jorgensen SE, et al. Functional IRF3 deficiency in a patient with herpes simplex encephalitis. J Exp Med. 2015; 212(9):1371–9. https://doi.org/10.1084/jem.20142274 PMID: 26261255

74. Mork N, Kofod-Olsen E, Sorensen KB, Bach E, Omhoff TF, Ostergaard L, et al. Mutations in the TLR3 signaling pathway and beyond in adult patients with herpes simplex encephalitis. Genes Immun. 2015; 16(8):552–66. https://doi.org/10.1038/gene.2015.46 PMID: 26513235

75. Zhang SY, Jouanguy E, Ugolini S, Smahi A, Elain G, Romero P, et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science. 2007; 317(5844):1522–7. https://doi.org/10.1126/science.1139552 PMID: 17872438

76. Menasria R, Boivin N, Lebel M, Piret J, Gooselin J, Boivin G. Both TRIF and IPS-1 adaptor proteins contribute to the cerebral innate immune response against herpes simplex virus 1 infection. J Virol. 2013; 87(13):7301–8. https://doi.org/10.1128/JVI.00991-13 PMID: 23596298

77. Fredericksen BL, Keller BC, Fornek J, Katze MG, Gale M Jr., Establishment and maintenance of the innate antiviral response to West Nile Virus involves both RIG-I and MDA5 signaling through IPS-1. J Virol. 2008; 82(2):609–16. https://doi.org/10.1128/JVI.01305-07 PMID: 17977974

78. Ejercito PM, Kieff ED, Roizman B. Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells. J Gen Virol. 1968; 2(3):357–64. https://doi.org/10.1099/0022-1317-2-3-357 PMID: 4300104

79. Cheng G, Brett ME, He B. Signals that dictate nuclear, nucleolar, and cytoplasmic shuttling of the γ34.5 protein of herpes simplex virus type 1. J Virol. 2002; 76(18):9434–45. https://doi.org/10.1128/jvi.76.18.9434-9445.2002 PMID: 12186925

80. Jingt X, Cerveny M, Yang K, He B. Replication of herpes simplex virus 1 depends on the γ34.5 functions that facilitate virus response to interferon and egress in the different stages of productive infection. J Virol. 2004; 78(14):7653–66. https://doi.org/10.1128/JVI.78.14.7653-7666.2004 PMID: 15220440

81. Wang Y, Yang Y, Wu S, Pan S, Zhou C, Ma Y, et al. p32 is a novel target for viral protein ICP34.5 of herpes simplex virus type 1 and facilitates viral nuclear egress. J Biol Chem. 2014; 289(52):35795–805. https://doi.org/10.1074/jbc.M114.603845 PMID: 25355318

82. Saito T, Hirai R, Loo YM, Owen D, Johnson CL, Sinha SC, et al. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc Natl Acad Sci U S A. 2007; 104(2):582–7. https://doi.org/10.1073/pnas.0606699104 PMID: 17190814

83. Liu X, MatreneC R, Gack MU, He B. Disassembly of the TRIM23-TBK1 complex by the Us11 protein of herpes simplex virus 1 impairs autophagy. J Virol. 2019; 93(17). https://doi.org/10.1128/JVI.00497-19 PMID: 31189704

84. Talon J, Horvath CM, Polley R, Basler CF, Muster T, Palese P, et al. Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. J Virol. 2000; 74(17):7989–96. https://doi.org/10.1128/jvi.74.17.7989-7996.2000 PMID: 10933707

85. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013; 29(1):15–21. https://doi.org/10.1093/bioinformatics/bts486
86. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014; 30(7):923–30. https://doi.org/10.1093/bioinformatics/btt656 PMID: 24227677

87. McCarthy DJ, Chen Y, Smyth GK. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res. 2012; 40(10):4288–97. https://doi.org/10.1093/nar/gks042 PMID: 22287627

88. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010; 26(1):139–40. https://doi.org/10.1093/bioinformatics/btp616 PMID: 19910308

89. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A practical and powerful approach to multiple testing. J Royal Statist Soci Series B (Methodological). 1995; 57(1):289–300.

90. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3(6):1101–8. https://doi.org/10.1038/nprot.2008.73 PMID: 18546601

91. Ma Y, Jin H, Valyi-Nagy T, Cao Y, Yan Z, He B. Inhibition of TANK binding kinase 1 by herpes simplex virus 1 facilitates productive infection. J Virol. 2012; 86(4):2188–96. https://doi.org/10.1128/JVI.05376-11 PMID: 22171259